NEW YORK – Revvity reported on Monday that its first diagnostics quarter revenues rose 4 percent year over year on growth in its immunodiagnostics business with contributions from its reproductive health business.

纽约——Revvity周一报告称，其第一季度诊断业务收入同比增长4%，这得益于免疫诊断业务的增长以及生殖健康业务的贡献。

For the quarter ended March 30, the Waltham, Massachusetts-based firm recorded total revenues of $664.8 million, up 2 percent from $649.9 million a year ago and beating analysts’ consensus estimate of $661.7 million. On an organic basis, the firm reported its revenues rose 4 percent year over year.

截至3月30日的季度，这家位于马萨诸塞州沃尔瑟姆的公司录得总收入6.648亿美元，较去年同期的6.499亿美元增长了2%，并超过了分析师普遍预期的6.617亿美元。按有机基础计算，该公司表示其收入同比增长了4%。

Revvity officials

Revvity官员

said in January

一月说的

that the firm expected improving revenues in 2025 with rising spending by pharma and biotech companies, although CEO Prahlad Singh said that the slope of recovery was uncertain over the full year and the company was assuming the current market conditions would prevail.

该公司预计，随着制药和生物技术公司支出的增加，2025年的收入将会增长。不过，首席执行官Prahlad Singh表示，全年复苏的斜率尚不确定，公司假设当前的市场状况将会持续。

The firm's Q1 diagnostics revenues rose to $324.4 million from $313.4 million in the year-ago quarter. Revenues were up 5 percent on an organic basis. Revvity's immunodiagnostics revenues rose in the high single digits globally while newborn screening revenues rose in the low single digits, it said..

该公司第一季度的诊断收入从去年同期的3.134亿美元增长至3.244亿美元。收入在有机基础上增长了5%。Revvity的免疫诊断收入在全球范围内增长了较高的个位数，而新生儿筛查收入则增长了较低的个位数。

Meanwhile, the company's life sciences revenues rose 1 percent to $340.4 million from $336.5 million a year earlier. The firm reported low single digit growth in pharma and biotech spending but a low single digit decline in academic and government spending. Its life sciences solutions business declined in the low single digits with declines in instrument sales but growth in reagent sales, while software revenues rose in the double digits..

同时，公司生命科学领域的收入增长了 1%，从一年前的 3.365 亿美元增至 3.404 亿美元。公司报告称，制药和生物技术支出呈现较低的个位数增长，而学术和政府支出则呈现较低的个位数下降。其生命科学解决方案业务出现较低的个位数下滑，仪器销售下降，但试剂销售增长，而软件收入则实现了两位数的增长。

The firm's R&D spending rose 6 percent to $53.6 million from $50.4 million a year earlier, while its SG&A spending fell 4 percent to $249.7 million from $260.6 million.

公司研发支出从一年前的 5040 万美元增加 6% 至 5360 万美元，而销售、一般和管理支出从 2.606 亿美元下降 4% 至 2.497 亿美元。

Revvity reported net income for the quarter of $42.2 million, or $.35 per share, compared to $26.0 million, or $21 per share, one year ago. The firm reported adjusted EPS off $1.01, compared to Wall Street's estimate of $.95 per share.

Revvity 报告本季度净利润为 4220 万美元，即每股 0.35 美元，而一年前为 2600 万美元，或每股 21 美元。该公司报告调整后每股收益为 1.01 美元，而华尔街的预期为每股 0.95 美元。

At the end of the quarter, the company had $1.14 billion in cash and cash equivalents.

季度末，该公司拥有 11.4 亿美元的现金及现金等价物。

Revvity raised its guidance for full fiscal year 2025 revenues and now expects it to be in the range of $2.83 billion to $2.87 billion, up from previous guidance of revenues in the range of $2.80 billion to $2.85 billion. The company expects organic revenue growth of 3 percent to 5 percent for the full year.

Revvity上调了对2025财年全年收入的预期，现在预计收入将在28.3亿美元至28.7亿美元之间，高于之前预期的28亿美元至28.5亿美元。公司预计全年有机收入增长将达到3%至5%。

The firm reaffirmed its previous adjusted EPS guidance to be in the range of $4.90 to $5.00..

公司重申了其先前调整后的每股收益指引，范围为4.90至5.00美元。